$11.66
-0.73-5.85%
Last update: Nov 12, 12:33 PM
Janux Therapeutics Inc
JANXNASDAQ
Janux Therapeutics fell 56.6% from $28.52 to $12.39, behind the S&P 500's +11.2%. Its worst day was Dec 3 (−49.8%), and its low came Nov 10 at $12.04.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Janux Therapeutics closed at its highest level of the year, 21.8% above where the year started.
+10.2% · S&P 500 +0.9%
Janux Therapeutics shares fell 49.8%, while the S&P 500 rose 0.1%.
Story events cover the past 12 months · Times ET
−49.8%, the year's worst day · S&P 500 +0.1%
Janux Therapeutics shares rose 14.1%, while the S&P 500 rose 0.5%.
+14.1%, the year's best day · S&P 500 +0.5%
EPS of $-0.51 beat the $-0.64 estimate on $0.00 revenue (est. $71,430.00).
−1.4% · S&P 500 −0.5%
EPS of $-0.39 beat the $-0.52 estimate on $3.7M revenue (est. $6.8M).
−2.5% · S&P 500 +0.8%
EPS of $-0.35 missed the $-0.28 estimate on $10.3M revenue (est. $21.8M).
−1.6% · S&P 500 +0.6%
EPS of $-0.34 beat the $-0.48 estimate on $9.3M revenue (est. $6.5M).
+9.8% · S&P 500 +0.3%
Where it ended: a close of $12.39 on Nov 11, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-0.51, revenue est. $6.4M).
Nothing in the past 12 months.
All JANX dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for JANX and SPY from Benzinga historical bars. Not investment advice.
